OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories
-
Form 144 Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Janux Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 4 Terns Pharmaceuticals, For: Jul 15 Filed by: ORBIMED ADVISORS LLC
-
Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 144 Terns Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 TELA Bio, Inc. For: Jun 28 Filed by: ORBIMED ADVISORS LLC
-
Form 144 TELA Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Disc Medicine, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Apollomics Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 144 Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
-
Form 13F-HR ORBIMED ADVISORS LLC For: Mar 31
-
Form 4 Corvus Pharmaceuticals, For: May 06 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: May 01 Filed by: ORBIMED ADVISORS LLC
-
MDxHealth Reports Q1-2024 Results and Announces Growth Capital from OrbiMed
-
SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F
-
Form 4 NeuroPace Inc For: Apr 24 Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: Apr 19 Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: Apr 16 Filed by: ORBIMED ADVISORS LLC
-
Form 4 NeuroPace Inc For: Apr 11 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 3/A Traws Pharma, Inc. For: Apr 01 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Enliven Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 3 Traws Pharma, Inc. For: Apr 01 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Q32 Bio Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 3 Q32 Bio Inc. For: Mar 25 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Adicet Bio, Inc. Filed by: ORBIMED ADVISORS LLC
-
Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference
-
Form SC 13D/A NextCure, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 144 Verona Pharma plc Filed by: ORBIMED ADVISORS LLC
-
Find Therapeutics Announces Appointment of Dr. Anthony Johnson to its Board of Directors
-
BlossomHill Therapeutics Closes $100 Million Series B Financing
-
OmniGuide(TM) Holdings and UROTECH (Medi-Globe Group Subsidiary) Announce Partnership to Expand Global Urology Patient Therapies
-
Form SC 13D/A Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A ALX ONCOLOGY HOLDINGS Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G InspireMD, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Verastem, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A SI-BONE, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G Scholar Rock Holding Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Protara Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A NeuroPace Inc Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Mersana Therapeutics, Filed by: ORBIMED ADVISORS LLC